2025 CNS Summit Series: Rewriting the Rules of Neurodegeneration, A Conversation with Arvinas CSO Angela Cacace, PhD

What if protein degradation could address neurodegenerative diseases, not just cancer? In this episode, Dr. Angela Cacace, CSO at Arvinas, speaks with Dr. Talar Hopyan, Global Head of CST at Syneos Health, about how the company is advancing a degrader targeting LRRK2 in Parkinson’s disease and why early-stage signals in healthy volunteers are raising new possibilities for CNS care. They discuss how Arvinas is engineering blood-brain barrier-penetrant molecules, the translational challenges in neurodegeneration and what’s required to move from platform to patient. What you’ll learn: How Arvinas is expanding targeted protein degradation into neurology Why LRRK2 degradation is a promising approach for Parkinson’s disease What it takes to translate platform innovation into measurable clinical outcomes The views expressed in this podcast belong solely to the speakers and do not represent those of their organization.  If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at https://www.syneoshealth.com/insights-hub. Like what you’re hearing? Be sure to rate and review us!  We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at [email protected].